HCV Cure Rates in Co-Infected Patients Can Be as High as HCV Mono-Infected Patients
November 24th 2017The results of a new study show that patients who are co-infected with the hepatitis C virus (HCV) and HIV can experience cure rates similar to individuals infected with HCV alone when both groups receive direct-acting antiviral drugs.
Read More
Merck Loses Big Money on HCV Drug
March 4th 2017Kenilworth, New Jersey-based Merck, will take a loss of $0.22 a share from last year’s fourth quarter. This will account for a total loss of $2.9 billion, or $1.9 billion after taxes. The pharmaceutical giant had previously reported a profit of $0.42 a share for that period.
Read More